CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

This study is a complex pediatric cancer trial testing new treatment approaches for children and teenagers newly diagnosed with acute myeloid leukemia (AML), a type of blood cancer that starts in the bone marrow. **You may be eligible if...** - Your child is from newborn age up to 18 years old - Your child has been newly diagnosed with AML (not caused by prior chemotherapy or bone marrow failure) - Your child has not received any prior AML treatment - Parents or legal guardians can provide written consent (and the child can give assent if appropriate) **You may NOT be eligible if...** - Your child has a different type of leukemia or a secondary (treatment-related) AML - Your child has previously been treated for AML - Consent/assent requirements are not met Talk to your doctor to see if this trial is right for you.